JP2022516651A - 二環式ピロロトリアゾールケトン化合物及びその使用方法 - Google Patents
二環式ピロロトリアゾールケトン化合物及びその使用方法 Download PDFInfo
- Publication number
- JP2022516651A JP2022516651A JP2021539523A JP2021539523A JP2022516651A JP 2022516651 A JP2022516651 A JP 2022516651A JP 2021539523 A JP2021539523 A JP 2021539523A JP 2021539523 A JP2021539523 A JP 2021539523A JP 2022516651 A JP2022516651 A JP 2022516651A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- triazole
- pharmaceutically acceptable
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 ketone compounds Chemical class 0.000 title claims description 133
- 125000002619 bicyclic group Chemical group 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 259
- 150000001875 compounds Chemical class 0.000 claims abstract description 194
- 201000010099 disease Diseases 0.000 claims abstract description 136
- 238000000034 method Methods 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 208000035475 disorder Diseases 0.000 claims description 122
- 150000003839 salts Chemical class 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 59
- 238000011282 treatment Methods 0.000 claims description 44
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 33
- 208000011580 syndromic disease Diseases 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 21
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 20
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 208000017169 kidney disease Diseases 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 18
- 208000018737 Parkinson disease Diseases 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 16
- 206010033799 Paralysis Diseases 0.000 claims description 16
- 208000033626 Renal failure acute Diseases 0.000 claims description 16
- 201000011040 acute kidney failure Diseases 0.000 claims description 16
- 208000021090 palsy Diseases 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 208000023105 Huntington disease Diseases 0.000 claims description 14
- 208000006011 Stroke Diseases 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 14
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 13
- 208000011231 Crohn disease Diseases 0.000 claims description 13
- 201000004681 Psoriasis Diseases 0.000 claims description 13
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 13
- 206010063837 Reperfusion injury Diseases 0.000 claims description 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 12
- 230000007850 degeneration Effects 0.000 claims description 12
- 201000010901 lateral sclerosis Diseases 0.000 claims description 12
- 208000005264 motor neuron disease Diseases 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
- 208000016192 Demyelinating disease Diseases 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 208000028867 ischemia Diseases 0.000 claims description 11
- 201000008383 nephritis Diseases 0.000 claims description 11
- 201000008482 osteoarthritis Diseases 0.000 claims description 11
- 230000000750 progressive effect Effects 0.000 claims description 11
- 230000009885 systemic effect Effects 0.000 claims description 11
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 10
- 208000032843 Hemorrhage Diseases 0.000 claims description 10
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 10
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 10
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 10
- 206010052779 Transplant rejections Diseases 0.000 claims description 10
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 10
- 208000034158 bleeding Diseases 0.000 claims description 10
- 230000000740 bleeding effect Effects 0.000 claims description 10
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 10
- 229960004316 cisplatin Drugs 0.000 claims description 10
- 230000001054 cortical effect Effects 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 238000007917 intracranial administration Methods 0.000 claims description 10
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 10
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 10
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 10
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 10
- 206010003694 Atrophy Diseases 0.000 claims description 9
- 208000010412 Glaucoma Diseases 0.000 claims description 9
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 9
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 9
- 230000037444 atrophy Effects 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 9
- 201000000585 muscular atrophy Diseases 0.000 claims description 9
- 201000006938 muscular dystrophy Diseases 0.000 claims description 9
- 208000006311 Pyoderma Diseases 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 7
- 206010012305 Demyelination Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 230000000366 juvenile effect Effects 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- FBORMSYFVQSNPV-UHFFFAOYSA-N 1-[7-fluoro-5-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-one Chemical compound CCC(=O)C1=NN2C(CC(C2=N1)F)C3=CN(N=C3)C FBORMSYFVQSNPV-UHFFFAOYSA-N 0.000 claims description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 4
- 206010053879 Sepsis syndrome Diseases 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 230000002123 temporal effect Effects 0.000 claims description 4
- CLELLYLGVVWSNC-UHFFFAOYSA-N (2,2-dimethyl-3-oxabicyclo[3.1.0]hexan-1-yl)-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone Chemical compound CC1(C)OCC(C2)C12C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O CLELLYLGVVWSNC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 3
- UBGABCPJLOUPOD-UHFFFAOYSA-N CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O UBGABCPJLOUPOD-UHFFFAOYSA-N 0.000 claims description 3
- ZQVFZBINUZNLET-UHFFFAOYSA-N CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O ZQVFZBINUZNLET-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 3
- 206010061481 Renal injury Diseases 0.000 claims description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 5
- 230000002956 necrotizing effect Effects 0.000 claims 4
- 206010048327 Supranuclear palsy Diseases 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 125000004122 cyclic group Chemical group 0.000 description 29
- 239000000243 solution Substances 0.000 description 26
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 239000000654 additive Substances 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000008499 blood brain barrier function Effects 0.000 description 12
- 210000001218 blood-brain barrier Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 238000009825 accumulation Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 208000037765 diseases and disorders Diseases 0.000 description 9
- 230000021597 necroptosis Effects 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 125000004430 oxygen atom Chemical group O* 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 229940127557 pharmaceutical product Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 230000001338 necrotic effect Effects 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 0 C*C(C1)c2nc(*)n[n]2C1(C)O* Chemical compound C*C(C1)c2nc(*)n[n]2C1(C)O* 0.000 description 4
- 108090000426 Caspase-1 Proteins 0.000 description 4
- 102000010170 Death domains Human genes 0.000 description 4
- 108050001718 Death domains Proteins 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 208000009796 Gangliosidoses Diseases 0.000 description 4
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 4
- 102000016871 Hexosaminidase A Human genes 0.000 description 4
- 108010053317 Hexosaminidase A Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 4
- 101710090077 NF-kappa-B essential modulator Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 4
- 201000007737 Retinal degeneration Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 208000026589 Wolman disease Diseases 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 201000006440 gangliosidosis Diseases 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000004001 thioalkyl group Chemical group 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 101710156256 Myosin phosphatase Rho-interacting protein Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 238000006068 polycondensation reaction Methods 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 208000013223 septicemia Diseases 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OUOQLEMKKVUYLC-UHFFFAOYSA-N 3,5-dibromo-1-(oxan-2-yl)-1,2,4-triazole Chemical compound N1=C(Br)N=C(Br)N1C1OCCCC1 OUOQLEMKKVUYLC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010010582 Congenital osteodystrophy Diseases 0.000 description 2
- 206010011777 Cystinosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000011518 Danon disease Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 208000007652 Dysostoses Diseases 0.000 description 2
- 201000001324 Dysostosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 2
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000004902 Iron regulatory protein 2 Human genes 0.000 description 2
- 108090001028 Iron regulatory protein 2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000028226 Krabbe disease Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 description 2
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000008955 Mucolipidoses Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 2
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- RYFGSKWVGYBXNB-STQMWFEESA-N N#Cc1cccc([C@H](C2)[n]3nc(C(C4CC4)=O)nc3[C@H]2F)c1 Chemical compound N#Cc1cccc([C@H](C2)[n]3nc(C(C4CC4)=O)nc3[C@H]2F)c1 RYFGSKWVGYBXNB-STQMWFEESA-N 0.000 description 2
- 108700011067 Necrosome Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- ADJGHHDLGNZOCP-LBPRGKRZSA-N O=C(C1CC1)c1n[n](CC[C@H]2c3ccccc3)c2n1 Chemical compound O=C(C1CC1)c1n[n](CC[C@H]2c3ccccc3)c2n1 ADJGHHDLGNZOCP-LBPRGKRZSA-N 0.000 description 2
- HXHYIBLISMREFM-QWRGUYRKSA-N O=C(C1CC1)c1n[n]([C@@H](C[C@@H]2F)c3cncc(F)c3)c2n1 Chemical compound O=C(C1CC1)c1n[n]([C@@H](C[C@@H]2F)c3cncc(F)c3)c2n1 HXHYIBLISMREFM-QWRGUYRKSA-N 0.000 description 2
- 101150071716 PCSK1 gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100027716 RanBP-type and C3HC4-type zinc finger-containing protein 1 Human genes 0.000 description 2
- 101710164093 RanBP-type and C3HC4-type zinc finger-containing protein 1 Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 208000021811 Sandhoff disease Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000007156 Spondylarthritis Diseases 0.000 description 2
- 102000019355 Synuclein Human genes 0.000 description 2
- 108050006783 Synuclein Proteins 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- HXHYIBLISMREFM-GHMZBOCLSA-N cyclopropyl-[(5R,7R)-7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3[C@H](C[C@H](C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-GHMZBOCLSA-N 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 201000004502 glycogen storage disease II Diseases 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 208000024557 hepatobiliary disease Diseases 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000007769 mucolipidosis Diseases 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- IQYRPZAMBNATNQ-UHFFFAOYSA-N n-methoxy-n-methylcyclopropanecarboxamide Chemical compound CON(C)C(=O)C1CC1 IQYRPZAMBNATNQ-UHFFFAOYSA-N 0.000 description 2
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000036964 tight binding Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYWVERKQKRXSL-PHDIDXHHSA-N (1r,4r)-2-oxa-5-azabicyclo[2.2.2]octane Chemical compound C1C[C@]2([H])CN[C@@]1([H])CO2 JNYWVERKQKRXSL-PHDIDXHHSA-N 0.000 description 1
- CJQNJRRDTPULTL-KNVOCYPGSA-N (1r,5s)-3-azabicyclo[3.2.1]octane Chemical compound C1[C@@]2([H])CC[C@]1([H])CNC2 CJQNJRRDTPULTL-KNVOCYPGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- HVHGJFORENHMIN-JGVFFNPUSA-N (5S,7R)-2-bromo-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol Chemical compound C1[C@H](N2C(=NC(=N2)Br)[C@@H]1O)C3=CC(=CN=C3)F HVHGJFORENHMIN-JGVFFNPUSA-N 0.000 description 1
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000006230 (methoxyethoxy)ethanyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- MMNSHNBVSJFTNA-UHFFFAOYSA-N 1h-phosphole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CP1 MMNSHNBVSJFTNA-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PMOIJEIPLOFHIO-UHFFFAOYSA-N 3-bromo-1-(oxan-2-yl)-1,2,4-triazole Chemical compound N1=C(Br)N=CN1C1OCCCC1 PMOIJEIPLOFHIO-UHFFFAOYSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GDSQTWDUCDSZEY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indazole Chemical compound C1CCCC2=C1C=NN2 GDSQTWDUCDSZEY-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- BXZSBDDOYIWMGC-UHFFFAOYSA-N 5-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(F)=C1 BXZSBDDOYIWMGC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RKZFPOGMBZTJKT-UHFFFAOYSA-N 7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-diene Chemical compound N1N=CC2=C1CC1CC21 RKZFPOGMBZTJKT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000004411 C5-C6 heterocyclyl group Chemical group 0.000 description 1
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
- UBGABCPJLOUPOD-KIYNQFGBSA-N CC(C)(CO)C(c1n[n]([C@@H](CC2F)c3ccccc3)c2n1)=O Chemical compound CC(C)(CO)C(c1n[n]([C@@H](CC2F)c3ccccc3)c2n1)=O UBGABCPJLOUPOD-KIYNQFGBSA-N 0.000 description 1
- MSWPUSCLYLQSOD-KBPBESRZSA-N CC(N(C1)CC1C(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O)=O Chemical compound CC(N(C1)CC1C(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O)=O MSWPUSCLYLQSOD-KBPBESRZSA-N 0.000 description 1
- FBORMSYFVQSNPV-IUCAKERBSA-N CCC(c1n[n]([C@@H](C[C@@H]2F)c3c[n](C)nc3)c2n1)=O Chemical compound CCC(c1n[n]([C@@H](C[C@@H]2F)c3c[n](C)nc3)c2n1)=O FBORMSYFVQSNPV-IUCAKERBSA-N 0.000 description 1
- IHHJAWHAIYOWJQ-AAEUAGOBSA-N C[C@@H](C1)c2nc(C(C(C)(C)COC(F)=[F])=O)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(C(C(C)(C)COC(F)=[F])=O)n[n]2[C@@H]1c1ccccc1 IHHJAWHAIYOWJQ-AAEUAGOBSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- KTPKWQKCSWBMEO-YUMQZZPRSA-N F[C@@H](C1)c2nc(Br)n[n]2[C@@H]1c1cncc(F)c1 Chemical compound F[C@@H](C1)c2nc(Br)n[n]2[C@@H]1c1cncc(F)c1 KTPKWQKCSWBMEO-YUMQZZPRSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- UCBCDYATPTZCCC-RYUDHWBXSA-N O=C(C1CC1)c1n[n]([C@@H](C[C@@H]2F)c3cc(Cl)ccc3)c2n1 Chemical compound O=C(C1CC1)c1n[n]([C@@H](C[C@@H]2F)c3cc(Cl)ccc3)c2n1 UCBCDYATPTZCCC-RYUDHWBXSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- JKPGXNOWXXDLSA-UHFFFAOYSA-N ethyl 3-(5-fluoropyridin-3-yl)-3-hydroxypropanoate Chemical compound FC=1C=C(C=NC=1)C(CC(=O)OCC)O JKPGXNOWXXDLSA-UHFFFAOYSA-N 0.000 description 1
- QMHIQUZBCPIUCY-UHFFFAOYSA-N ethyl 3-(5-fluoropyridin-3-yl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)c1cncc(F)c1 QMHIQUZBCPIUCY-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000001976 hemiacetal group Chemical group 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- VXIIOIWGHFXJSW-UHFFFAOYSA-N imidazolidin-2-one;1-methylpiperidine Chemical compound O=C1NCCN1.CN1CCCCC1 VXIIOIWGHFXJSW-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- PGCFLXMMCWKPDU-UHFFFAOYSA-N methyl 5-fluoropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(F)=C1 PGCFLXMMCWKPDU-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NQBKFULMFQMZBE-UHFFFAOYSA-N n-bz-3-benzanthronylpyrazolanthron Chemical compound C12=CC=CC(C(=O)C=3C4=CC=CC=3)=C2C4=NN1C1=CC=C2C3=C1C1=CC=CC=C1C(=O)C3=CC=C2 NQBKFULMFQMZBE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
本願は、2019年1月11日出願の米国仮特許出願第62/791118号(全内容が参照により本明細書に援用される)の利益を主張するものである。
1)Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. and Vandenabeele, P. (2014) Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 15, 135-147.
2)Newton, K. (2015) RIPK1 and RIPK3: critical regulators of inflammation and cell death. Trends Cell Biol. 25, 347-353.
3)de Almagro, M. C. and Vucic, D. (2015) Necroptosis: Pathway diversity and characteristics. Semin. Cell Dev. Biol. 39, 56-62.
4)Chen, Z. J. (2012) Ubiquitination in signaling to and activation of IKK. Immunological reviews. 246, 95-106.
5)O’Donnell, M. A., Legarda-Addison, D., Skountzos, P., Yeh, W. C. and Ting, A. T. (2007) Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr. Biol. 17, 418-424.
6)Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D. P., Langlais, C., Hupe, M., Cain, K., MacFarlane, M., Hacker, G. and Leverkus, M. (2011) cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 43, 449-463.
7)Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreault, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J. and Barker, P. A. (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689-700.
8)Wang, L., Du, F. and Wang, X. (2008) TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133, 693-703.
9)He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L. and Wang, X. (2009) Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100-1111.
10)Cho, Y. S., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M. and Chan, F. K. (2009) Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112-1123.
11)Degterev, A., Hitomi, J., Germscheid, M., Ch’en, I. L., Korkina, O., Teng, X., Abbott, D., Cuny, G. D., Yuan, C., Wagner, G., Hedrick, S. M., Gerber, S. A., Lugovskoy, A. and Yuan, J. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4, 313-321.
12)Newton, K., Dugger, D. L., Wickliffe, K. E., Kapoor, N., de Almagro, M. C., Vucic, D., Komuves, L., Ferrando, R. E., French, D. M., Webster, J., Roose-Girma, M., Warming, S. and Dixit, V. M. (2014) Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 343, 1357-1360.
13)Kaiser, W. J., Sridharan, H., Huang, C., Mandal, P., Upton, J. W., Gough, P. J., Sehon, C. A., Marquis, R. W., Bertin, J. and Mocarski, E. S. (2013) Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288, 31268-31279.
14)Zhao, J., Jitkaew, S., Cai, Z., Choksi, S., Li, Q., Luo, J. and Liu, Z. G. (2012) Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Nat. Acad. Sci. U.S.A. 109, 5322-5327.
15)Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X. and Wang, X. (2012) Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase. Cell 148, 213-227.
16)Linkermann, A. and Green, D. R. (2014) Necroptosis. N. Engl. J. Med. 370, 455-465.
17)Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A. and Yuan, J. (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112-119.
18)Takahashi, N., Duprez, L., Grootjans, S., Cauwels, A., Nerinckx, W., DuHadaway, J. B., Goossens, V., Roelandt, R., Van Hauwermeiren, F., Libert, C., Declercq, W., Callewaert, N., Prendergast, G. C., Degterev, A., Yuan, J. and Vandenabeele, P. (2012) Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 3, e437.
19)Harris, P. A., Bandyopadhyay, D., Berger, S. B., Campobasso, N., Capriotti, C. A., Cox, J. A., Dare, L., Finger, J. N., Hoffman, S. J., Kahler, K. M., Lehr, R., Lich, J. D., Nagilla, R., Nolte, R. T., Ouellette, M. T., Pao, C. S., Schaeffer, M. C., Smallwood, A., Sun, H. H., Swift, B. A., Totoritis, R. D., Ward, P., Marquis, R. W., Bertin, J. and Gough, P. J. (2013) Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med. Chem. Lett. 4, 1238-1243.
20)Najjar, M., Suebsuwong, C., Ray, S. S., Thapa, R. J., Maki, J. L., Nogusa, S., Shah, S., Saleh, D., Gough, P. J., Bertin, J., Yuan, J., Balachandran, S., Cuny, G. D. and Degterev, A. (2015) Structure Guided Design of Potent and Selective Ponatinib-Based Hybrid Inhibitors for RIPK1. Cell Rep. 24, 1850-60.
21)国際特許公開第2014/125444号
22)国際特許公開第2017/004500号
{上式中、
R1は、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、C1-C6アルキル-N(RN)2、フェニル、ベンジル、4~8員ヘテロシクリル、及び5~6員ヘテロアリールからなる群より選択され;ここでR1は、隣接するカルボニルに炭素原子によって結合しており、且つR1は、F、Cl、Br、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、C1-C6アルキル-N(RN)2、ヒドロキシル、ヒドロキシメチル、シアノ、シアノメチル、シアノエチル、C(O)C1-C6アルキル、フェニル、ベンジル、CH2-(C3-C6シクロアルキル)、5~6員ヘテロアリール、及びCH2-(5~6員ヘテロアリール)からなる群より選択される1又は2個の置換基によって置換されていてもよく;
各RNは、独立に、H、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、及びC1-C6ハロアルキルからなる群より選択されるか;又は2つのRNは、隣接するNと一緒になって4~6員環を形成していてもよく;
R2は、フェニル、ピラゾリル、及びピリジニルからなる群より選択され、これらのそれぞれは、無置換であるか、又はハロゲン、C1-C4アルキル、C1-C4ハロアルキル、C1-C4アルコキシ、C1-C4ハロアルコキシ、及びシアノからなる群より選択される1~3個の置換基で置換されていてもよく;
R3a及びR3bは、それぞれ独立に、水素又はハロである}
を有する化合物又はその薬学的に許容される塩を提供し、
上記化合物は、以下から選択される:
シクロプロピル(7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン;
(2,2-ジメチル-3-オキサビシクロ[3.1.0]ヘキサン-1-イル)-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;
3-ヒドロキシ-2,2-ジメチル-1-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
3-(ジフルオロメトキシ)-2,2-ジメチル-1-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
1-[rac-(5S,7S)-7-フルオロ-5-(1-メチルピラゾール-4-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
1-(3-((5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-カルボニル)アゼチジン-1-イル)エタン-1-オン;
3-[rac-(5S,7S)-2-(シクロプロパンカルボニル)-7-フルオロ-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-5-イル]ベンゾニトリル;
シクロプロピル-[rac-(5S,7S)-5-(3-クロロフェニル)-7-フルオロ-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;
シクロプロピル-[rac-(7S)-7-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;及び
シクロプロピル((5S,7S)-7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン;及び
シクロプロピル((5R,7R)-7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン。
本明細書で提供される場合、全ての化学式及び一般的化学構造は、当業者が理解するように、原子間の適切な価数と化学的に安定な結合を提供すると解釈されるものとする。必要に応じて、置換基は、隣接する複数の原子に結合している場合がある(例えば、アルキルは2つの結合が存在するメチレンを含む)。
本発明のいくつかの実施態様は、一般式I:
{上式中、
R1は、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、C1-C6アルキル-N(RN)2、フェニル、ベンジル、4~8員ヘテロシクリル、及び5~6員ヘテロアリールからなる群より選択され;ここでR1は、隣接するカルボニルに炭素原子によって結合しており、且つR1は、F、Cl、Br、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、C1-C6アルキル-N(RN)2、ヒドロキシル、ヒドロキシメチル、シアノ、シアノメチル、シアノエチル、C(O)C1-C6アルキル、フェニル、ベンジル、CH2-(C3-C6シクロアルキル)、5~6員ヘテロアリール、及びCH2-(5~6員ヘテロアリール)からなる群より選択される1又は2個の置換基によって置換されていてもよく;
各RNは、独立に、H、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、及びC1-C6ハロアルキルからなる群より選択されるか;又は2つのRNは、隣接するNと一緒になって4~6員環を形成していてもよく;
R2は、フェニル、ピラゾリル、及びピリジニルからなる群より選択され、これらのそれぞれは、無置換であるか、又はハロゲン、C1-C4アルキル、C1-C4ハロアルキル、C1-C4アルコキシ、C1-C4ハロアルコキシ、及びシアノからなる群より選択される1~3個の置換基で置換されていてもよく;
R3a及びR3bは、それぞれ独立に、水素又はハロである}
を有する化合物又はその薬学的に許容される塩を提供し、
上記化合物は、以下から選択される:
シクロプロピル(7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン;
(2,2-ジメチル-3-オキサビシクロ[3.1.0]ヘキサン-1-イル)-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;
3-ヒドロキシ-2,2-ジメチル-1-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
3-(ジフルオロメトキシ)-2,2-ジメチル-1-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
1-[rac-(5S,7S)-7-フルオロ-5-(1-メチルピラゾール-4-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
1-(3-((5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-カルボニル)アゼチジン-1-イル)エタン-1-オン;
3-[rac-(5S,7S)-2-(シクロプロパンカルボニル)-7-フルオロ-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-5-イル]ベンゾニトリル;
シクロプロピル-[rac-(5S,7S)-5-(3-クロロフェニル)-7-フルオロ-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;
シクロプロピル-[rac-(7S)-7-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;及び
シクロプロピル((5S,7S)-7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン。
本明細書で提供されるのは、本発明の化合物(又はその立体異性体、幾何異性体、互変異性体、溶媒和物、代謝産物、同位体、薬学的に許容される塩若しくはプロドラッグ)及び治療的に不活性な担体、希釈剤又は添加物を含有する薬学的組成物又は医薬、並びに本発明の化合物を用いてそのような組成物及び医薬を調製する方法である。一例では、式Iの化合物は、生理学的に許容される担体、すなわち、生薬の投与形態に使用される用量と濃度でレシピエントに対して毒性でない担体と、適切なpHと所望の純度で、周囲温度で混合することによって製剤化されてもよい。製剤のpHは主に、特定の用途及び化合物の濃度に依存するが、好ましくは約3から約8までの範囲である。一例では、式Iの化合物は、pH5の酢酸バッファーに配合される。別の実施態様において、式Iの化合物は、滅菌である。該化合物は、例えば、固体又は非晶質組成物として、凍結乾燥製剤として、又は水溶液として保存されてもよい。
いくつかの実施態様において、本発明の化合物は、RIP1キナーゼ活性を阻害する。したがって、本発明の化合物は、この経路によって媒介され、炎症及び/又はネクロプトーシス細胞死に関連する疾患及び障害の治療に有用である。
いくつかの実施態様において、本発明の化合物は、本明細書に記載の疾患及び障害の治療において、本発明の1種以上の他の化合物、又は1種以上の他の治療剤と、それらの任意の組み合わせとして組み合わされる。例えば、本発明の化合物と、上記のものから選択される疾患又は障害の治療に有用であることが知られている他の治療剤を同時に、順次に、又は別々に投与することができる。
ACN アセトニトリル
Boc tert-ブトキシカルボニル
DAST ジエチルアミノ硫黄トリフルオリド
DCE 1,2-ジクロロエタン
DCM ジクロロメタン
DMF N,N-ジメチルホルムアミド
DMSO ジメチルスルホキシド
DPPH 2,2-ジフェニル-1-ピクリルヒドラジル
HPLC 高圧液体クロマトグラフィー
LCMS 液体クロマトグラフィー質量分析
PCC クロロクロム酸ピリジニウム
RP 逆相
RT又はRT 保持時間
SEM 2-(トリメチルシリル)エトキシメチル
SFC 超臨界流体クロマトグラフィー
TFA トリフルオロ酢酸
THF テトラヒドロフラン
以下の実施例の特定の合成方法に加えて、例えば、スキーム1(式中、Rは低級アルキルであり、出現するごとに同じであっても異なっていてもよく、TBSはtert-ブチルジメチルクロロシリルであり、THPはテトラヒドロピラニルであり、Pivはピバレートであり、R1及びR2は本明細書で定義されている通りである)の手順に従って、本発明の追加の化合物を調製することができる。
シクロプロピル-[(5R,7R)-7-フルオロ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン及びシクロプロピル-[(5S,7S)-7-フルオロ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン
5-フルオロニコチン酸(40g、283mmol)のメタノール(200mL)溶液に塩化チオニル(31mL、425mmol)を加えた。混合物を90℃で18時間撹拌し、減圧下で濃縮した。残留物を酢酸エチル(400mL)で希釈し、飽和重炭酸ナトリウム水溶液(100mL)、ブライン(50mL)で洗浄し、硫酸ナトリウム上で乾燥させ、減圧下で濃縮して、粗製のメチル 5-フルオロピリジン-3-カルボキシレート(32g、73%)を淡褐色固体として得た。
リチウムビス(トリメチシリル)アミド(1.0M、テトラヒドロフラン中、500mL、500mmol)のテトラヒドロフラン(500mL)溶液に、窒素雰囲気下で-78℃で酢酸エチル(35mL、358mmol)を加えた。15分間撹拌後、メチル 5-フルオロピリジン-3-カルボキシレート(50g、322mmol)のテトラヒドロフラン(50mL)溶液を滴下した。混合物を2時間撹拌し、飽和塩化アンモニウム水溶液(300mL)の添加によりクエンチした。得られた溶液を酢酸エチル(3x500mL)で抽出した。合わせた有機層を重硫酸カリウム(500mL)、ブライン(300mL)で洗浄し、硫酸ナトリウム上で乾燥させ、減圧下で濃縮して、粗製のエチル 3-(5-フルオロ-3-ピリジル)-3-オキソ-プロパノエート(64g、94%)を褐色の油として得た。
エチル 3-(5-フルオロ-3-ピリジル)-3-オキソ-プロパノエート(64g、303mmol)のメタノール(400mL)溶液に、0℃で水素化ホウ素ナトリウム(5.73g、151mmol)を加えた。混合物を1.5時間撹拌した後、飽和塩化アンモニウム水溶液(200mL)を加えてクエンチした。得られた混合物を酢酸エチル(3x300mL)で抽出した。合わせた有機層をブライン(300mL)で洗浄し、硫酸ナトリウム上で乾燥させ、減圧下で濃縮して、粗製のエチル 3‐(5‐フルオロ‐3‐ピリジル)‐3‐ヒドロキシ‐プロパノエート(60g、93%)を褐色の油として得た。
N,N-ジメチルホルムアミド(500mL)にエチル 3-(5-フルオロ-3-ピリジル)-3-ヒドロキシ-プロパノエート(60g、281mmol)とイミダゾール(38g、562.83mmol)を入れた混合物に、20℃でtert-ブチルジメチルクロロシラン(47g、309mmol)を加えた。添加後、混合物を20℃で18時間撹拌し、濾過した。濾液を水(1000mL)で希釈し、酢酸エチル(3x300mL)で抽出した。合わせた有機層を飽和重炭酸ナトリウム水溶液(2x300mL)、ブライン(200mL)で洗浄し、硫酸ナトリウム上で乾燥させ、減圧下で濃縮した。残留物をカラムクロマトグラフィー(シリカゲル、10~200メッシュ、石油エーテル中0~5%酢酸エチル)により精製し、エチル 3‐[tert‐ブチル(ジメチル)シリル]オキシ‐3‐(5‐フルオロ‐3‐ピリジル)プロパノエート(40g、44%)を無色の油として得た。
テトラヒドロフラン(400mL)にN,O-ジメチルヒドロキシルアミン塩酸塩(24g、244.3mmol)とエチル 3-[tert-ブチル(ジメチル)シリル]オキシ-3-(5-フルオロ-3-ピリジル)プロパノエート(40g、122.2mmol)を入れた混合物に、窒素雰囲気下、-78℃で塩化イソプロピルマグネシウムを加えた。混合物を-70℃で16時間撹拌し、その後飽和塩化アンモニウム水溶液(400mL)の添加によってクエンチした。得られた溶液を酢酸エチルで抽出した。合わせた有機層をブライン(300mL)で洗浄し、硫酸ナトリウム上で乾燥させ、減圧下で濃縮した。残留物をカラムクロマトグラフィー(シリカゲル、10~200メッシュ、石油エーテル中0~20%酢酸エチル)により精製し、3‐[tert‐ブチル(ジメチル)シリル]オキシ‐3‐(5‐フルオロ‐3‐ピリジル)-N-メトキシ-N-メチル-プロパンアミド(25g、60%)を無色の油として得た。
3-[tert-ブチル(ジメチル)シリル]オキシ-3-(5-フルオロ-3-ピリジル)-N-メトキシ-N-メチル-プロパンアミド(25.0g、73.0mmol)と3,5-ジブロモ-1-テトラヒドロピラン-2-イル-1,2,4-トリアゾール(29.5g、94.9mmol)のテトラヒドロフラン(300mL)溶液に塩化イソプロピルマグネシウム(テトラヒドロフラン中2.0M、47.5mL、95.0mmol)を窒素雰囲気下-70℃で加えた。添加後、混合物を30℃で18時間撹拌し、その後水(200mL)の添加によってクエンチした。混合物を酢酸エチル(3x200mL)で抽出した。合わせた有機層を硫酸ナトリウム上で乾燥させ、減圧下で濃縮した。残留物をカラムクロマトグラフィー(シリカゲル、100~200メッシュ、石油エーテル中0~30%酢酸エチル)により精製し、1-(5-ブロモ-2-テトラヒドロピラン-2-イル-1,2,4-トリアゾール-3-イル)-3-[tert-ブチルl(ジメチル)シリル]オキシ-3-(5-フルオロ-3-ピリジル)プロパン-1-オン(15.0g、40%)を明褐色の油として得た。
1-(5-ブロモ-2-テトラヒドロピラン-2-イル-1,2,4-トリアゾール-3-イル)-3-[tert-ブチル(ジメチル)シリル]オキシ-3-(5-フルオロ-3-ピリジル)プロパン-1-オン(15.0g、29.2mmol)のエタノール溶液(225mL)に0℃で水素化ホウ素ナトリウム(829mg、21.9mmol)を加えた。添加後、混合物を0℃で16時間撹拌し、濃縮乾固した。残留物を水(500mL)で希釈し、酢酸エチル(2x300mL)で抽出した。合わせた有機層をブラインで洗浄し、硫酸ナトリウム上で乾燥させ、減圧下で濃縮して、粗製の1‐(5‐ブロモ‐2‐テトラヒドロピラン‐2‐イル‐1,2,4‐トリアゾール‐3‐イル)‐3‐[tert‐ブチル(ジメチル)シリル]オキシ‐3‐(5‐フルオロ‐3‐ピリジル)プロパン‐1‐オール(14.0g、93%)を褐色の油として得た。
1-(5-ブロモ-2-テトラヒドロピラン-2-イル-1,2,4-トリアゾール-3-イル)-3-[tert-ブチル(ジメチル)シリルオキシ-3-(5-フルオロ-3-ピリジル)プロパン-1-オール(14.0g、27.2mmol)のジクロロメタン(175mL)及びトリエチルアミン(11.4mL、81.5mmol)溶液に、塩化ピバロイル(5mL、40.74mmol)及び4-ジメチルアミノピリジン(3.3g、27.2mmol)を加えた。混合物を25℃で1.5時間撹拌し、水(300mL)の添加によりクエンチした。混合物をジクロロメタン(3x500mL)で抽出した。合わせた有機層を硫酸ナトリウム上で乾燥させ、減圧下で濃縮した。残留物をカラムクロマトグラフィー(シリカゲル、100~200メッシュ、石油エーテル中0~15%酢酸エチル)により精製し、[1-(5-ブロモ-2-テトラヒドロピラン-2-イル-1,2,4-トリアゾール-3-イル)-3-[tert-ブチル(ジメチル)シリル]オキシ-3-(5-フルオロ-3-ピリジル)プロピル]2,2-ジメチルプロパノエート(16g、98%)を無色の油として得た。
[1-(5-ブロモ-2-テトラヒドロピラン-2-イル-1,2,4-トリアゾール-3-イル)-3-[tert-ブチル(ジメチル)シリル]オキシ-3-(5-フルオロ-3-ピリジル)プロピル]2,2-ジメチルプロパノエート(10.0g、16.7mmol)のメタノール(20mL)溶液に、0℃で塩酸(メタノール中4.0M、40.0mL、16.7mmol)を加えた。得られた溶液を25℃で2時間撹拌し、減圧下で濃縮した。残留物をカラムクロマトグラフィー(シリカゲル、100~200メッシュ、石油エーテル中0~100%酢酸エチル)により精製し、1-(3-ブロモ-1H-1,2,4-トリアゾール-5-イル)-3-(5-フルオロピリジン-3-イル)-3-ヒドロキシプロピルピバレート(3.6g、54%)を黄色固体として得た。LC-MS RT=0.749min,m/z=401.0[M+H]+.
LCMS(水中5~95%アセトニトリル+0.03%トリフルオロ酢酸を1.5分間かけて)保持時間0.749分、ESI+では[M+H]=401.0であった。
1-(3-ブロモ-1H-1,2,4-トリアゾール-5-イル)-3-(5-フルオロピリジン-3-イル)-3-ヒドロキシプロピルピバレート(2.5g、6.23mmol)のジクロロメタン(50mL)溶液に、25℃でトリエチルアミン(25mL、6.23mmol)及び塩化メタンスルホニル(4.23g、36.93mmol)を加えた。混合物を16時間撹拌し、減圧下で濃縮した。残留物をカラムクロマトグラフィー(シリカゲル、100~200メッシュ、石油エーテル中0~50%酢酸エチル)により精製し、[トランス-2-ブロモ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-7-イル]-2,2-ジメチルプロパノエート(600mg、25%)を白色固体として得た。LC-MS RT=0.845min,m/z=383.1[M+H]+.
LCMS(水中5~95%アセトニトリル+0.03%トリフルオロ酢酸を1.5分間かけて)保持時間0.845分、ESI+では[M+H]=383.1であった。
[トランス-2-ブロモ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-7-イル]2,2-ジメチルプロパノエート(200mg、0.52mmol)のメタノール(5mL)及び水(2mL)溶液に、25℃で水酸化ナトリウム(63mg、1.57mmol)を加えた。得られた混合物を2時間撹拌し、減圧下で濃縮した。残留物にジクロロメタン/メタノール混合液(20:1)(50mL)を加えて濾過した。濾液を減圧下で濃縮し、粗製のトランス-2-ブロモ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-7-オール(180mg、90%)を白色固体として得た。LC-MS RT=0.609min,m/z=299.9[M+H]+.
LCMS(水中5~95%アセトニトリル+0.03%トリフルオロ酢酸を1.5分間かけて)保持時間0.609分、ESI+では[M+H]=299.0であった。
トランス-2-ブロモ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-7-オール(570mg、1.91mmol)のトルエン(10mL)溶液に-78℃でジエチルアミノ硫黄トリフルオリド(1.3g、7.62mmol)を加えた。混合物を0℃で1時間撹拌した。混合物をジクロロメタン(50mL)で希釈し、氷水(50mL)に注いだ。分離した有機層を硫酸ナトリウム上で乾燥させ、減圧下で濃縮した。残留物をフラッシュクロマトグラフィー(シリカゲル、100~200メッシュ、石油エーテル中0~50%酢酸エチル)により精製し、(シス-2-ブロモ-7-フルオロ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール(170mg、30%)を白色固体として得た。
シス-2-ブロモ-7-フルオロ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール(80mg、0.27mmol)及びN-メトキシ-N-メチル-シクロプロパンカルボキサミド(100mg、0.77mmol)のテトラヒドロフラン(5mL)溶液に0℃で塩化イソプロピルマグネシウム(テトラヒドロフラン中2.0M、0.35mL、0.70mmol)を加えた。混合物を0℃で1時間撹拌し、飽和塩化アンモニウム水溶液(10mL)の添加によりクエンチした。得られた混合物を酢酸エチル(3x10mL)で抽出した。合わせた有機層を硫酸ナトリウム上で乾燥させ、減圧下で濃縮した。残留物を分取用TLC(石油エーテル中75%酢酸エチル、Rf=0.5)により精製し、シクロプロピル-[シス-7-フルオロ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン(17mg、20%)を黄色固体として得た。このラセミ体をキラルSFCで分離して、任意に割り当てた以下のものを得た。
シクロプロピル-[(5R,7R)-7-フルオロ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン(ピーク1、保持時間=4.154分)。(8.3mg、51%)1H NMR(400MHz,CD3OD)δ8.54-8.53(m,1H),8.46(s,1H),7.60-7.55(m,1H),6.25-6.08(m,1H),5.86-5.83(m,1H),3.85-3.76(m,1H),3.32-2.88(m,2H),1.30-1.12(m,4H).LC-MS RT=0.807min,m/z=290.9[M+H]+.
LCMS(水中5~95%アセトニトリル+0.03%トリフルオロ酢酸を1.5分間かけて)保持時間0.807分、ESI+では[M+H]=290.9であった。
シクロプロピル-[(5S,7S)-7-フルオロ-5-(5-フルオロ-3-ピリジル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン(ピーク2、保持時間=4.835分)。(8.2mg、48%)1H NMR(400MHz,CD3OD)δ8.54-8.52(m,1H),8.46(s,1H),7.59-7.55(m,1H),6.24-6.08(m,1H),5.85-5.82(m,1H),3.86-3.82(m,1H),3.07-2.95(m,2H),1.29-1.11(m,4H).
LC-MS RT=0.812min,m/z=291.0[M+H]+.
LCMS(水中5~95%アセトニトリル+0.03%トリフルオロ酢酸を1.5分間かけて)保持時間0.812分、ESI+では[M+H]=291.0であった。
SFC条件:カラム:Phenomenex-Amylose-1(250mm×30mm、5um)移動相:A:CO2 B:エタノール(0.1%NH3 H2O。勾配:Bの5%~35%。流量:50mL/分。
ステップ1のフルオロピリジニルエステルを適当なフェニル又はピラゾリルエステルに置き換えること、及びステップ13のN-メトキシ-N-メチル-シクロプロパンカルボキサミドを適当なカルボキサミドに置き換えることにより、上記の手順のバリエーションを用いて追加の化合物を作成した。これらの化合物を、実施例1及び2の化合物とともに、各化合物のプロトンNMR、質量スペクトル及びKi値(後述のようにして決定)とともに、表1に示す。特に記載のない限り、各構造に示される立体化学は単一の立体異性体の相対立体配置を表し、絶対配置(すなわち「R」及び/又は「S」)は任意に割り当てられる。
本発明の化合物は、以下に記載するRIP1K活性を阻害するそれらの能力について試験された。
受容体相互作用タンパク質キナーゼ(RIPK1)がアデノシン-5’-三リン酸(ATP)の加水分解を触媒する能力を、Transcreener ADP(アデノシン-5’-二リン酸)アッセイ(BellBrook Labs)を使用してモニターする。バキュロウイルス感染昆虫細胞発現系に由来する精製ヒトRIP1キナーゼドメイン(2-375)(50nM)を、30mMのMgCl2、1mMのジチオスレイトール、50μMのATP、0.002%のBrij-35、及び0.5%のジメチルスルホキシド(DMSO)を含む50mMのHEPESバッファー(pH7.5)中で2時間、試験混合物とインキュベートする。追加の12mMのEDTA及び55μg/mL ADP2抗体及び4nM ADP-AlexaFluor(登録商標)633トレーサーを含む1X Bell Brooks StopバッファーB(20mM HEPES(ph7.5)、40mMエチレンジアミン四酢酸及び0.02%Brij-35)により反応をクエンチする。抗体に結合したトレーサーが反応の間に生成されたADPによって変位することで、蛍光偏光が減少し、FPマイクロプレートリーダーM1000で633nmのレーザー励起によって測定される。画分活性を試験品濃度に対してプロットした。Genedata Screenerソフトウエア(Genedata;スイス、バーゼル)を用いて、データを見かけの強結合阻害定数(tight-binding apparent inhibition constant)(Ki app)Morrisonの式[Williams, J.W. and Morrison, J. F. (1979) The kinetics of reversible tight-binding inhibition. Methods Enzymol 63: 437-67]に適合させた。以下の方程式を使用して、画分活性及びKi appを計算した。
上式中、[E]T及び[I]Tは、それぞれ活性酵素と試験品の総濃度である。
Claims (46)
- 式(I):
{上式中、
R1は、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、C1-C6アルキル-N(RN)2、フェニル、ベンジル、4~8員ヘテロシクリル、及び5~6員ヘテロアリールからなる群より選択され;ここでR1は、隣接するカルボニルに炭素原子によって結合しており、且つR1は、F、Cl、Br、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、C1-C6アルキル-N(RN)2、ヒドロキシル、ヒドロキシメチル、シアノ、シアノメチル、シアノエチル、C(O)C1-C6アルキル、フェニル、ベンジル、CH2-(C3-C6シクロアルキル)、5~6員ヘテロアリール、及びCH2-(5~6員ヘテロアリール)からなる群より選択される1又は2個の置換基によって置換されていてもよく;
各RNは、独立に、H、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシ、及びC1-C6ハロアルキルからなる群より選択されるか;又は2つのRNは、隣接するNと一緒になって4~6員環を形成していてもよく;
R2は、フェニル、ピラゾリル、及びピリジニルからなる群より選択され、これらのそれぞれは、無置換であるか、又はハロゲン、C1-C4アルキル、C1-C4ハロアルキル、C1-C4アルコキシ、C1-C4ハロアルコキシ、及びシアノからなる群より選択される1~3個の置換基で置換されていてもよく;
R3a及びR3bは、それぞれ独立に、水素又はハロである}
の化合物であって、
シクロプロピル(7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン;
(2,2-ジメチル-3-オキサビシクロ[3.1.0]ヘキサン-1-イル)-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;
3-ヒドロキシ-2,2-ジメチル-1-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
3-(ジフルオロメトキシ)-2,2-ジメチル-1-[rac-(5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
1-[rac-(5S,7S)-7-フルオロ-5-(1-メチルピラゾール-4-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]プロパン-1-オン;
1-(3-((5S,7S)-7-フルオロ-5-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-カルボニル)アゼチジン-1-イル)エタン-1-オン;
3-[rac-(5S,7S)-2-(シクロプロパンカルボニル)-7-フルオロ-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-5-イル]ベンゾニトリル;
シクロプロピル-[rac-(5S,7S)-5-(3-クロロフェニル)-7-フルオロ-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;
シクロプロピル-[rac-(7S)-7-フェニル-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル]メタノン;
シクロプロピル((5S,7S)-7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン;及び
シクロプロピル((5R,7R)-7-フルオロ-5-(5-フルオロピリジン-3-イル)-6,7-ジヒドロ-5H-ピロロ[1,2-b][1,2,4]トリアゾール-2-イル)メタノン
から選択される化合物又はその薬学的に許容される塩。 - 請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩と治療上不活性な担体とを含む薬学的組成物。
- 治療的活性物質としての使用のための、請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩。
- パーキンソン病、レビー小体病、多系統萎縮症、パーキンソンプラス症候群、タウパシー、アルツハイマー病、前頭側頭型認知症、筋萎縮性側索硬化症、脊髄性筋萎縮症、原発性側索硬化症、ハンチントン病、虚血、脳卒中、頭蓋内出血、脳出血、筋ジストロフィー、進行性筋萎縮症、偽性球麻痺、進行性球麻痺、脊髄性筋萎縮症、遺伝性筋萎縮症、末梢神経障害、進行性核上性麻痺、皮質基底核変性症、及び脱髄疾患からなる群より選択される疾患又は障害の治療のための、請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩。
- 炎症性腸障害又は疾患(IBD)、過敏性腸症候群(IBS)、クローン病、潰瘍性大腸炎、緑内障、乾癬、壊疽性膿皮症、乾癬性関節炎、関節リウマチ、脊椎関節炎、若年性特発性関節炎、及び変形性関節症からなる群より選択される疾患又は障害の治療のための、請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩。
- 急性腎障害(AKI)、移植片拒絶反応又は損傷、固形臓器の虚血再灌流障害、移植片機能発現遅延(DGF)、シスプラチン誘発性腎障害、腎炎誘発性腎障害、敗血症、及び全身性炎症反応症候群(SIRS)からなる群より選択される疾患又は障害の治療のための、請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩。
- パーキンソン病、レビー小体病、多系統萎縮症、パーキンソンプラス症候群、タウパシー、アルツハイマー病、前頭側頭型認知症、筋萎縮性側索硬化症、脊髄性筋萎縮症、原発性側索硬化症、ハンチントン病、虚血、脳卒中、頭蓋内出血、脳出血、筋ジストロフィー、進行性筋萎縮症、偽性球麻痺、進行性球麻痺、脊髄性筋萎縮症、遺伝性筋萎縮症、末梢神経障害、進行性核上性麻痺、皮質基底核変性症、及び脱髄疾患からなる群より選択される疾患又は障害の治療のための、請求項1~12のいずれか一項に記載の化合物若しくは組成物又はその薬学的に許容される塩の使用。
- 炎症性腸障害又は疾患(IBD)、過敏性腸症候群(IBS)、クローン病、潰瘍性大腸炎、緑内障、乾癬、壊疽性膿皮症、乾癬性関節炎、関節リウマチ、脊椎関節炎、若年性特発性関節炎、及び変形性関節症からなる群より選択される疾患又は障害の治療のための、請求項1~12のいずれか一項に記載の化合物若しくは組成物又はその薬学的に許容される塩の使用。
- 急性腎障害(AKI)、移植片拒絶反応又は損傷、固形臓器の虚血再灌流障害、移植片機能発現遅延(DGF)、シスプラチン誘発性腎障害、腎炎誘発性腎障害、敗血症、及び全身性炎症反応症候群(SIRS)からなる群より選択される疾患又は障害の治療のための、請求項1~12のいずれか一項に記載の化合物若しくは組成物又はその薬学的に許容される塩。
- パーキンソン病、レビー小体病、多系統萎縮症、パーキンソンプラス症候群、タウパシー、アルツハイマー病、前頭側頭型認知症、筋萎縮性側索硬化症、脊髄性筋萎縮症、原発性側索硬化症、ハンチントン病、虚血、脳卒中、頭蓋内出血、脳出血、筋ジストロフィー、進行性筋萎縮症、偽性球麻痺、進行性球麻痺、脊髄性筋萎縮症、遺伝性筋萎縮症、末梢神経障害、進行性核上性麻痺、皮質基底核変性症、及び脱髄疾患からなる群より選択される疾患又は障害の治療のための医薬の調製のための、請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩の使用。
- 炎症性腸障害又は疾患(IBD)、過敏性腸症候群(IBS)、クローン病、潰瘍性大腸炎、緑内障、乾癬、壊疽性膿皮症、乾癬性関節炎、関節リウマチ、脊椎関節炎、若年性特発性関節炎、及び変形性関節症からなる群より選択される疾患又は障害の治療のための医薬の調製のための、請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩の使用。
- 急性腎障害(AKI)、移植片拒絶反応又は損傷、固形臓器の虚血再灌流障害、移植片機能発現遅延(DGF)、シスプラチン誘発性腎障害、腎炎誘発性腎障害、敗血症、及び全身性炎症反応症候群(SIRS)からなる群より選択される疾患又は障害の治療のための医薬の調製のための、請求項1~12のいずれか一項に記載の化合物又はその薬学的に許容される塩の使用。
- 効果的な治療量の請求項1~12のいずれか一項に記載の化合物若しくは組成物又はその薬学的に許容される塩の対象への投与を含む、対象における疾患又は障害の治療のための方法であって、疾患又は障害が、パーキンソン病、レビー小体病、多系統萎縮症、パーキンソンプラス症候群、タウパシー、アルツハイマー病、前頭側頭型認知症、筋萎縮性側索硬化症、脊髄性筋萎縮症、原発性側索硬化症、ハンチントン病、虚血、脳卒中、頭蓋内出血、脳出血、筋ジストロフィー、進行性筋萎縮症、偽性球麻痺、進行性球麻痺、脊髄性筋萎縮症、遺伝性筋萎縮症、末梢神経障害、進行性核上性麻痺、皮質基底核変性症、及び脱髄疾患からなる群より選択される、方法。
- 効果的な治療量の請求項1~12のいずれか一項に記載の化合物若しくは組成物又はその薬学的に許容される塩の対象への投与を含む、対象における疾患又は障害の治療のための方法であって、疾患又は障害が、炎症性腸障害又は疾患(IBD)、過敏性腸症候群(IBS)、クローン病、潰瘍性大腸炎、緑内障、乾癬、壊疽性膿皮症、乾癬性関節炎、関節リウマチ、脊椎関節炎、若年性特発性関節炎、及び変形性関節症からなる群より選択される、方法。
- 効果的な治療量の請求項1~12のいずれか一項に記載の化合物若しくは組成物又はその薬学的に許容される塩の対象への投与を含む、対象における疾患又は障害の治療のための方法であって、疾患又は障害が、急性腎障害(AKI)、移植片拒絶反応又は損傷、固形臓器の虚血再灌流障害、移植片機能発現遅延(DGF)、シスプラチン誘発性腎障害、腎炎誘発性腎障害、敗血症、及び全身性炎症反応症候群(SIRS)からなる群より選択される、方法。
- 疾患又は障害がアルツハイマー病である、請求項24に記載の方法。
- 疾患又は障害が多発性硬化症である、請求項24に記載の方法。
- 疾患又は障害がパーキンソン病である、請求項24に記載の方法。
- 疾患又は障害が筋萎縮性側索硬化症である、請求項24に記載の方法。
- 疾患又は障害がハンチントン病である、請求項24に記載の方法。
- 疾患又は障害が脊髄性筋萎縮症である、請求項24に記載の方法。
- 疾患又は障害が炎症性腸障害又は疾患(IBD)である、請求項25に記載の方法。
- 疾患又は障害が過敏性腸症候群(IBS)である、請求項25に記載の方法。
- 疾患又は障害がクローン病である、請求項25に記載の方法。
- 疾患又は障害が潰瘍性大腸炎である、請求項25に記載の方法。
- 疾患又は障害が乾癬である、請求項25に記載の方法。
- 疾患又は障害が壊疽性膿皮症である、請求項25に記載の方法。
- 疾患又は障害が乾癬性関節炎である、請求項25に記載の方法。
- 疾患又は障害が関節リウマチである、請求項25に記載の方法。
- 疾患又は障害が脊椎関節炎である、請求項25に記載の方法。
- 疾患又は障害が若年性特発性関節炎である、請求項25に記載の方法。
- 疾患又は障害が急性腎障害(AKI)である、請求項26に記載の方法。
- 疾患又は障害が移植片拒絶反応又は損傷である、請求項26に記載の方法。
- 疾患又は障害が固形臓器の虚血再灌流障害である、請求項26に記載の方法。
- 疾患又は障害が移植片機能発現遅延(DGF)である、請求項26に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962791118P | 2019-01-11 | 2019-01-11 | |
US62/791,118 | 2019-01-11 | ||
PCT/US2020/012908 WO2020146615A1 (en) | 2019-01-11 | 2020-01-09 | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022516651A true JP2022516651A (ja) | 2022-03-01 |
JPWO2020146615A5 JPWO2020146615A5 (ja) | 2023-01-19 |
Family
ID=69528972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021539523A Pending JP2022516651A (ja) | 2019-01-11 | 2020-01-09 | 二環式ピロロトリアゾールケトン化合物及びその使用方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210340151A1 (ja) |
EP (1) | EP3908586B1 (ja) |
JP (1) | JP2022516651A (ja) |
CN (1) | CN113302193A (ja) |
AR (1) | AR119673A1 (ja) |
TW (1) | TW202043229A (ja) |
WO (1) | WO2020146615A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240025912A1 (en) * | 2022-05-19 | 2024-01-25 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
CN100386068C (zh) | 2002-12-03 | 2008-05-07 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
MX2014013407A (es) | 2012-05-22 | 2014-11-26 | Hoffmann La Roche | Dipiridilaminas sustituidas y uso de las mismas. |
WO2014111496A1 (en) | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
TWI638815B (zh) | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類(一) |
BR112015027381A8 (pt) | 2013-05-01 | 2018-01-30 | Hoffmann La Roche | pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos |
EA038235B1 (ru) | 2013-05-01 | 2021-07-28 | Ф.Хоффманн-Ля Рош Аг | Бигетероарильные соединения и их применения |
MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
WO2016027253A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
WO2016142310A1 (en) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
MA50356A (fr) * | 2017-10-11 | 2021-04-21 | Hoffmann La Roche | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 |
-
2020
- 2020-01-09 AR ARP200100056A patent/AR119673A1/es unknown
- 2020-01-09 JP JP2021539523A patent/JP2022516651A/ja active Pending
- 2020-01-09 EP EP20704652.5A patent/EP3908586B1/en active Active
- 2020-01-09 TW TW109100698A patent/TW202043229A/zh unknown
- 2020-01-09 CN CN202080008933.9A patent/CN113302193A/zh active Pending
- 2020-01-09 WO PCT/US2020/012908 patent/WO2020146615A1/en unknown
-
2021
- 2021-07-08 US US17/371,001 patent/US20210340151A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR119673A1 (es) | 2022-01-05 |
TW202043229A (zh) | 2020-12-01 |
WO2020146615A1 (en) | 2020-07-16 |
EP3908586A1 (en) | 2021-11-17 |
EP3908586B1 (en) | 2022-12-21 |
US20210340151A1 (en) | 2021-11-04 |
CN113302193A (zh) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3781571B1 (en) | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) | |
CN110072863B (zh) | Rip1激酶抑制剂及使用方法 | |
JP7349359B2 (ja) | 二環式ピリドンラクタム及びその使用方法。 | |
JP7362600B2 (ja) | Rip1キナーゼ阻害剤として使用するための二環式化合物 | |
JP6890179B2 (ja) | 二環式アミド化合物及びその使用方法 | |
BR112020000771A2 (pt) | compostos de cetona bicíclica e métodos de uso dos mesmos | |
US11072617B2 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
JP2022516651A (ja) | 二環式ピロロトリアゾールケトン化合物及びその使用方法 | |
RU2797922C2 (ru) | Бициклические кетоны и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230105 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230105 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240716 |